Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Genomic Health Inc. (GHDX - Analyst Report) continues to demonstrate the clinical and economic merits of its Oncotype DX breast cancer test. The company recently featured positive data from 22 clinical studies at the St. Gallen International Breast Cancer Conference.

The latest data on Oncotype DX breast cancer test displayed its ability to alter clinical decisions associated with individual cancer treatment by drawing attention to critical questions. Additionally, the test provides economic benefits to health care systems on the back of accurate disease diagnosis and treatment selection.

Findings from the decision impact data from France, Israel, Spain, Germany, UK and the U.A.E. reassert that Oncotype DX alters physician treatment recommendations. The inference from these studies validate similar findings from 15 previously reported Oncotype DX clinical utility studies from the U.S., Canada, Europe, Japan, Australia,  Israel and Mexico.

Further, five health economic analyses from France, the Netherlands, Ireland, Hungary and Mexico establish the cost effectiveness of Oncotype DX ensuring considerable savings for health care systems. According to results from the analyses conducted in France, the use of Oncotype DX will prevent unnecessary chemotherapy for patients and result in savings of €5 million. Additionally, Genomic Health demonstrated positive findings from nine other studies.

The uncontested results from across the globe acknowledge the proficiency of Oncotype DX test as the only genomic test proven to predict chemotherapy benefit. The latest results further enhance the efficacy of the company’s lead product.

Peer reviewed validation data for Oncotype DX should help Genomic Health gain foothold and reimbursement in new markets. Currently, the company has established significant reimbursements in Canada, Germany, UK, Ireland, Spain, Greece, Saudi Arabia and Israel. We believe that higher global adoption of Oncotype DX should improve overall growth for Genomic Health.

The stock carries a Zacks Rank #3 (Hold). While we remain on the sidelines for Genomic Health, we believe that other medical stocks such as Edwards Lifesciences (EW - Analyst Report), Conceptus and Abaxis (ABAX - Analyst Report) warrant a look as each carry a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
BITAUTO HOLD BITA 35.33 +14.82%
ANI PHARMACE ANIP 24.79 +14.66%
E-HOUSE CHIN EJ 10.99 +9.24%
CANADIAN SOL CSIQ 26.97 +7.15%
INTL CONS AI ICAGY 33.30 +5.38%